A delegation from Inno Bio paid a visit to the D-8 Secretariat on 07 March, 2018 and discussed cooperation in pharmaceutical products, particularly cancer-related medicine. The delegation was led by Mr. Mohd Zaid Abdul Jalil, CEO of the company. 

Inno Bio is the pioneer in development and production of biosimilar items for life-threatening diseases such as, breast cancer, leukemia, blood disorders and rheumatoid arthritis. Inno Bio Ventures won the D-8 Technology Transfer Award 2015 together with Aryogen Pharmed Co. for the development of ARYOSEVEN & ALTEBREL as biosimilar products. Inno Bio is geared up in commercialization of biosimilar products using its cGMP facilities, with support from Aryogen for both Malaysian and southeast Asian markets. Recently, Inno Bio Ventures signed an MoU with Nobel Pharmaceuticals, a renowned Turkish pharmaceutical company to develop common biotechnological products. It hopes to expand its market to other D-8 Member States and aims at organizing a workshop for the D-8 Member States to share their capacities, facilities, technology and expertise. 

 Ambassador Dato’ Ku Jaafar Ku Shaari, D-8 Secretary-General, welcomed the initiative and interest of Inno Bio to cater to the goals of the D-8 Organization. He assured the delegation that the Secretariat was ready for assistance. He also mentioned that a detailed proposal on their interest would help concretise the mode of cooperation between the D-8 and the Inno Bio.